Hetal S. Kocinsky

518 total citations
21 papers, 416 citations indexed

About

Hetal S. Kocinsky is a scholar working on Molecular Biology, Surgery and Immunology. According to data from OpenAlex, Hetal S. Kocinsky has authored 21 papers receiving a total of 416 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 5 papers in Surgery and 5 papers in Immunology. Recurrent topics in Hetal S. Kocinsky's work include Ion Transport and Channel Regulation (7 papers), Complement system in diseases (5 papers) and Hepatitis C virus research (5 papers). Hetal S. Kocinsky is often cited by papers focused on Ion Transport and Channel Regulation (7 papers), Complement system in diseases (5 papers) and Hepatitis C virus research (5 papers). Hetal S. Kocinsky collaborates with scholars based in United States, Canada and United Kingdom. Hetal S. Kocinsky's co-authors include Peter S. Aronson, Diane W Dynia, John Orlowski, Tong Wang, Adriana C. C. Girardi, Thao Nguyen, Daniel Biemesderfer, SueAnn Mentone, Rakhilya Murtazina and Mark Donowitz and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Journal of the American Society of Nephrology.

In The Last Decade

Hetal S. Kocinsky

20 papers receiving 414 citations

Peers

Hetal S. Kocinsky
Daiei Takahashi Japan
Sabina Jeleń Denmark
Beiru Zhang China
Sylviane Couette France
Anne Debonneville Switzerland
Joon-Young Kim South Korea
Hewang Lee United States
Erik R. Walp United States
Diego López-Guerra Spain
Beilei Zhao China
Daiei Takahashi Japan
Hetal S. Kocinsky
Citations per year, relative to Hetal S. Kocinsky Hetal S. Kocinsky (= 1×) peers Daiei Takahashi

Countries citing papers authored by Hetal S. Kocinsky

Since Specialization
Citations

This map shows the geographic impact of Hetal S. Kocinsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hetal S. Kocinsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hetal S. Kocinsky more than expected).

Fields of papers citing papers by Hetal S. Kocinsky

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hetal S. Kocinsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hetal S. Kocinsky. The network helps show where Hetal S. Kocinsky may publish in the future.

Co-authorship network of co-authors of Hetal S. Kocinsky

This figure shows the co-authorship network connecting the top 25 collaborators of Hetal S. Kocinsky. A scholar is included among the top collaborators of Hetal S. Kocinsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hetal S. Kocinsky. Hetal S. Kocinsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Remuzzi, Giuseppe, Bradley P. Dixon, Fádi Fakhouri, et al.. (2022). POS-048 PHASE 3, RANDOMIZED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PEGCETACOPLAN IN TREATMENT OF C3G OR IC-MPGN. Kidney International Reports. 7(6). S459–S459. 2 indexed citations
2.
Pickering, Matthew C., Bradley P. Dixon, Patrick D. Walker, et al.. (2022). POS-047 PHASE 2 STUDY TO EVALUATE EFFICACY AND SAFETY OF PEGCETACOPLAN IN THE TREATMENT OF PATIENTS WITH POSTTRANSPLANT RECURRENCE OF C3G OR IC MPGN. Kidney International Reports. 7(6). S458–S459. 2 indexed citations
3.
Kelleher, Catherine L. & Hetal S. Kocinsky. (2020). Novel Complement Therapeutics in Development as Potential Treatment for Renal Disease. Advances in Chronic Kidney Disease. 27(2). 95–103. 3 indexed citations
4.
Dixon, Bradley P., Larry A. Greenbaum, Liwei Huang, et al.. (2020). C3 Inhibition with Pegcetacoplan Targets the Underlying Disease Process of C3 Glomerulopathy (C3G) and Improves Proteinuria. Journal of the American Society of Nephrology. 31(10S). 577–577. 6 indexed citations
5.
Kocinsky, Hetal S., David Apelian, Michael Geffner, et al.. (2018). SaO018FACTOR D INHIBITION WITH ACH-4471 TO REDUCE COMPLEMENT ALTERNATIVE PATHWAY HYPERACTIVITY AND PROTEINURIA IN C3 GLOMERULOPATHY: PRELIMINARY PROOF OF CONCEPT DATA. Nephrology Dialysis Transplantation. 33(suppl_1). i322–i322. 1 indexed citations
6.
Huang, Mingjun, Wengang Yang, Steven D. Podos, et al.. (2017). Inhibition of complement alternative pathway by ACH-4471, the first clinical investigational orally-administered inhibitor of complement factor D. Molecular Immunology. 89. 200–201.
7.
Gane, Edward, Christian Schwabe, Michael Mader, et al.. (2015). LP06 : Sustained virologic response after ACH-3102 and sofosbuvir treatment for 8 or 6 weeks: A phase 2 “proxy” study. Journal of Hepatology. 62. S266–S266. 10 indexed citations
8.
Chen, Tiane, Hetal S. Kocinsky, Boyoung Cha, et al.. (2014). Cyclic GMP Kinase II (cGKII) Inhibits NHE3 by Altering Its Trafficking and Phosphorylating NHE3 at Three Required Sites. Journal of Biological Chemistry. 290(4). 1952–1965. 48 indexed citations
9.
Lawitz, Eric, John M. Hill, Bradley Vince, et al.. (2013). 847 ACH-2684 DEMONSTRATES POTENT VIRAL SUPPRESSION IN GENOTYPE 1 HEPATITIS C PATIENTS WITH AND WITHOUT CIRRHOSIS: SAFETY, PHARMACOKINETIC, AND VIRAL KINETIC ANALYSIS. Journal of Hepatology. 58. S347–S347. 5 indexed citations
10.
11.
Hayashi, Hisayoshi, Atsushi Tamura, Sachiko Tsukita, et al.. (2013). Ezrin Is Required for the Functional Regulation of the Epithelial Sodium Proton Exchanger, NHE3. PLoS ONE. 8(2). e55623–e55623. 17 indexed citations
12.
Hui, James Hoi Po, et al.. (2013). 1201 NO CLINICALLY SIGNIFICANT PHARMACOKINETIC INTERACTION BETWEEN SOVAPREVIR AND ACH-3102 IN HEALTHY VOLUNTEERS. Journal of Hepatology. 58. S488–S488. 1 indexed citations
13.
Yang, Guo‐Min, Yanan Zhao, J. Fabrycki, et al.. (2013). 1199 FINDINGS FROM CLINICAL VIROLOGY STUDIES ON ACH-3102 ARE CONSISTENT WITH PRECLINICAL OBSERVATIONS ON ITS IMPROVED POTENCY AGAINST GENOTYPE-1a HCV AND RESISTANT VARIANTS. Journal of Hepatology. 58. S487–S488. 1 indexed citations
14.
Ruiz-Garcı́a, Ana, et al.. (2013). A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers. The Journal of Clinical Pharmacology. 54(5). 555–562. 20 indexed citations
15.
16.
Murtazina, Rakhilya, Olga Kovbasnjuk, Tian-E Chen, et al.. (2011). NHERF2 is necessary for basal activity, second messenger inhibition, and LPA stimulation of NHE3 in mouse distal ileum. American Journal of Physiology-Cell Physiology. 301(1). C126–C136. 36 indexed citations
17.
Dynia, Diane W, et al.. (2009). NHE3 function and phosphorylation are regulated by a calyculin A-sensitive phosphatase. American Journal of Physiology-Renal Physiology. 298(3). F745–F753. 26 indexed citations
18.
Kocinsky, Hetal S., Diane W Dynia, Tong Wang, & Peter S. Aronson. (2007). NHE3 phosphorylation at serines 552 and 605 does not directly affect NHE3 activity. American Journal of Physiology-Renal Physiology. 293(1). F212–F218. 64 indexed citations
19.
Alexander, R. Todd, Anatoly Malevanets, Anne M. Durkan, et al.. (2007). Membrane Curvature Alters the Activation Kinetics of the Epithelial Na+/H+ Exchanger, NHE3. Journal of Biological Chemistry. 282(10). 7376–7384. 28 indexed citations
20.
Kocinsky, Hetal S., Adriana C. C. Girardi, Daniel Biemesderfer, et al.. (2005). Use of phospho-specific antibodies to determine the phosphorylation of endogenous Na+/H+ exchanger NHE3 at PKA consensus sites. American Journal of Physiology-Renal Physiology. 289(2). F249–F258. 93 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daiei Takahashi Breakdown of academic impact, for papers by Sabina Jeleń Breakdown of academic impact, for papers by Beiru Zhang Breakdown of academic impact, for papers by Sylviane Couette Breakdown of academic impact, for papers by Anne Debonneville Breakdown of academic impact, for papers by Joon-Young Kim Breakdown of academic impact, for papers by Hewang Lee Breakdown of academic impact, for papers by Erik R. Walp Breakdown of academic impact, for papers by Diego López-Guerra Breakdown of academic impact, for papers by Beilei Zhao
Rankless by CCL
2026